SCHEMBL3300396

SCHEMBL3300396

C#CCN(C(=O)OC(C)(C)C)[C@@H]1CCc2ccc(O)cc21

nearest known ligand 0.61

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
ACHE P22303 8/20 0.49
MAOA P21397 5/20 0.46
MAOB P27338 5/20 0.46
NQO2 P16083 1/20 0.37
MTNR1A P48039 1/20 0.37
MTNR1B P49286 1/20 0.37
BCHE P06276 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3299930 1.00 ACHE (0.49) ACHEMAOAMAOBNQO2MTNR1A
SCHEMBL5899449 0.88 ACHE (0.48) ACHEMAOAMAOBBCHE
SCHEMBL3378409 0.85 MAOA (0.56) ACHEMAOAMAOBBCHE
SCHEMBL3378411 0.85 MAOA (0.56) ACHEMAOAMAOBBCHE
SCHEMBL5794544 0.85 ACHE (0.46) ACHEMAOAMAOBBCHE
SCHEMBL5899576 0.85 ACHE (0.46) ACHEMAOAMAOB
SCHEMBL3299004 0.83 ACHE (0.56) ACHEMAOAMAOBBCHE
SCHEMBL12450286 0.82 ACHE (0.41) ACHEMAOAMAOBBCHE
SCHEMBL3300195 0.81 ACHE (0.58) ACHEMAOAMAOBBCHE
SCHEMBL4186578 0.81 ACHE (0.54) ACHEMAOAMAOBBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8609719-B2 Propargylated aminoindans, processes for preparation, and uses thereof YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2013-12-17 US disclosed
US-20100093848-A1 PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2010-04-15 US disclosed
US-7625946-B2 Propargylated aminoindans, processes for preparation, and uses thereof YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2009-12-01 US disclosed
WO-2007100583-A2 PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2007-09-07 WO disclosed
US-20070203232-A1 Propargylated aminoindans, processes for preparation, and uses thereof TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203232-A1 Propargylated aminoindans, processes for preparation, and uses thereof PRMT3, PRMT1, PNMT ACHE 76/4885MAOA 511/4885MAOB 510/4885
US-20100093848-A1 PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF DNPEP, PEPD, ACHE ACHE 3/4885MAOA 482/4885MAOB 1332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.